Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Symbravo medication information ema europa eu?Novartis patent term dabrafenib?What's the advised delay for milk post lipitor?When oxcarbazepine patent expired?Brenzavvy discontinuation?
See the DrugPatentWatch profile for cetuximab
Cetuximab was developed by ImClone Systems and its partner company Bristol-Myers Squibb (BMS). Early development is commonly attributed to ImClone, with later clinical and commercialization efforts involving BMS. [1][2]
After development work by ImClone, the drug was commercialized under the brand Erbitux. The commercialization rights and market presence were tied to Bristol-Myers Squibb’s role as partner for later-stage development and distribution. [1][2]
Public, widely cited development history for cetuximab centers on the ImClone–BMS collaboration. Other firms are more commonly seen later as developers of competing antibodies, biosimilars, or next-generation EGFR therapies rather than as original cetuximab developers. [1][2]
1 2
Other Questions About Cetuximab :